Company news
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
(600196)"Shanghai Fosun Pharmaceutical (Group) Co., Ltd."Indicative Announcement on Approval of a Controlled Subsidiary's Drug for Clinical Trials in Australia
November 4, 2026
(600196)"Shanghai Fosun Pharmaceutical (Group) Co., Ltd."Announcement on Progress of the Private Equity Investment Fund Established with the Company's Participation
November 4, 2026
(600196)"Shanghai Fosun Pharmaceutical (Group) Co., Ltd."Announcement on Progress of the Drug Clinical Trial of a Controlled Subsidiary
November 4, 2026
(600196)"Shanghai Fosun Pharmaceutical (Group) Co., Ltd."Announcement on Resignation of Senior Executive
November 2, 2026
(600196)"Shanghai Fosun Pharmaceutical (Group) Co., Ltd."Report for Q3 2026
October 27, 2026
(600196)"Shanghai Fosun Pharmaceutical (Group) Co., Ltd."Pre-announcement on the Q3 2026 Performance Briefing
October 27, 2026
(600196)"Shanghai Fosun Pharmaceutical (Group) Co., Ltd."Announcement on Release of Pledge of Certain Shares Held by Shareholder
October 26, 2026
(600196)"Shanghai Fosun Pharmaceutical (Group) Co., Ltd."Announcement on Progress in Providing Guarantees for Controlled Subsidiaries
October 16, 2026
(600196)"Shanghai Fosun Pharmaceutical (Group) Co., Ltd."Announcement on Results of Reserved Grant under the 2025 A-Share Stock Option Incentive Plan
September 28, 2026
A New International Medical Approach Aimed at Reversing Diabetes has Officially Launched in Shenzhen, China
September 28, 2026
Announcement on Signing of Cooperation and License Agreement by Controlled Subsidiary
September 23, 2026
Announcement on Release of Pledge of Certain Shares Held by Shareholder
September 21, 2026
Fosun Health Anjur Forum Rawatan Onkologi Antarabangsa Pertama di Foshan; International Oncology Alliance Ditubuhkan Secara Rasmi
September 20, 2026
Fosun Health Hosts First International Oncology Treatment Forum in Foshan; International Oncology Alliance Officially Established
September 19, 2026
Announcement on Pledge and Release of Pledge on Certain Shares Held by a Shareholder
September 18, 2026
Announcement on Acceptance of the Drug Registration Application of Controlled Subsidiary
September 11, 2026
Announcement on the Public Disclosure and Review Opinion of the List of Participants for the Reserved Grant under the 2025 A-Share Stock Option Incentive Plan Issued by the Remuneration and Appraisal Committee of the Board of Directors
September 8, 2026
Fosun Pharma Announces H-Share Repurchase Plan of Up to HK$ 1 Billion
September 6, 2026
Announcement on Extension of Loans to a Controlled Subsidiary and Related Party Transaction
September 4, 2026
Announcement on a Controlled Subsidiary's Drug Obtaining Registration Approval for a New Indication
September 3, 2026
Announcement on Reserved Grant of the 2025 H-Share Restricted Share Unit Plan
August 28, 2026
Indicative Announcement on Obtaining Registration Approval for the Licensed Drug
August 27, 2026
Fosun Pharma Announces 2026 Interim Results
August 25, 2026
Announcement on Progress of the Drug Clinical Trial of a Controlled Subsidiary
August 13, 2026
Announcement on Progress in Providing Guarantee for Controlled Subsidiary
August 7, 2026
Announcement on Receipt of Drug Registration Approval by a Controlled Subsidiary
August 3, 2026
Announcement on Completion of Private Investment Fund Filing for the Investment Fund Established with the Company's Participation as an Investor
July 29, 2026
Announcement on Controlled Subsidiary's Drug Obtaining Approval for Clinical Trial
July 24, 2026
Announcement on Release of Pledge of Certain Shares of Shareholder
July 22, 2026
Announcement on Implementation of A-Share Dividend Distribution for 2025
July 16, 2026
Announcement on Pledge of Partial Shares Held by a Shareholder
July 15, 2026
Announcement on Progress in Providing Guarantee for Holding Subsidiary
July 3, 2026
Announcement on Resolutions of the 33rd (Extraordinary) Meeting of the 10th Board of Directors
July 1, 2026
Announcement on Progress in Transfer of Partnership Interests and Progress in Private Equity Investment Fund Invested by the Partnership
June 29, 2026
Indicative Announcement on Obtaining EU Approval of a New Indication for a Drug Developed by the Holding Subsidiary
June 25, 2026
Announcement on Progress in Providing Guarantee for Holding Subsidiary
June 22, 2026
Announcement on Holding Subsidiary's Passing GMP Compliance Inspection
June 17, 2026
Announcement on Resolutions of the 2025 Annual General Meeting, the 2nd A-Share Shareholders' Meeting in 2026, and the 2nd H-Share Shareholders' Meeting in 2026
June 16, 2026
Announcement on New Drug Indication Obtaining Registration Approval for a Holding Subsidiary
June 15, 2026
Indicative Announcement on Convening the 2025 Annual General Meeting, the 2nd A-Share Shareholders' Meeting in 2026, and the 2nd H-Share Shareholders' Meeting in 2026
June 12, 2026
Announcement on Obtaining Approval of Drug Registration by the Holding Subsidiary
May 29, 2026
Announcement on Progress in Participating in Setting up Private Equity Investment Fund
May 28, 2026
Announcement on Outward Investment and Related Party Transactions
May 26, 2026
Announcement on Holding Subsidiary’s Drug Obtaining Approval for Clinical Trial
May 21, 2026
Announcement on Acceptance of Drug Registration Application of Holding Subsidiary
May 13, 2026
Notice on Convening the 2025 Annual General Meeting, the 2nd A-Share Shareholders' Meeting in 2026, and the 2nd H-Share Shareholders' Meeting in 2026
May 11, 2026
Announcement on Holding Subsidiary’s Drug Obtaining Approval for Clinical Trial from FDA
May 10, 2026
Fosun Pharma Announces Q1 2026 Results: Net Profit Attributable to Shareholders After Deducting Non-Recurring Gains and Losses Increased by 21.96% YoY, With Strong Pipeline Execution
April 28, 2026
Arcera Life Sciences and Fosun Pharma launch long-term collaboration framework
April 28, 2026
Announcement on Progress in Participation in Establishing a Private Equity Investment Fund and Proposed Disposal of Assets
April 23, 2026
Decks
- H1 2026 Earnings Presentation
Earnings · 45 slides · Oct 12, 2026
- Q1 2026 Earnings Presentation
Earnings · 45 slides · 2026
- Q1 2025 Earnings Presentation
Earnings · 44 slides · 2025
- Q3 2025 Earnings Presentation
Earnings · 45 slides · 2025